Deeper Knowledge, Faster

  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Deloitte
Covington
Johnson and Johnson
AstraZeneca
McKinsey
Novartis
Dow
Farmers Insurance
Argus Health
US Army

Generated: January 16, 2018

DrugPatentWatch Database Preview

Details for Patent: 6,017,927

« Back to Dashboard

Which drugs does patent 6,017,927 protect, and when does it expire?

Patent 6,017,927 protects VESICARE and is included in one NDA.

Protection for VESICARE has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has thirty-one patent family members in twenty-two countries.
Summary for Patent: 6,017,927
Title: Quinuclidine derivatives and medicinal composition thereof
Abstract:Quinuclidine derivatives represented by general following general formula (I), salts, N-oxides or quaternary ammonium salts thereof, and medicinal compositions containing the same. ##STR1## The compound has an antagonistic effect on muscarinic M.sub.3 receptors and is useful as a preventive or remedy for urologic diseases, respiratory diseases or digestive diseases.
Inventor(s): Takeuchi; Makoto (Ibaraki, JP), Naito; Ryo (Ibaraki, JP), Hayakawa; Masahiko (Ibaraki, JP), Okamoto; Yoshinori (Ibaraki, JP), Yonetoku; Yasuhiro (Ibaraki, JP), Ikeda; Ken (Chiba, JP), Isomura; Yasuo (Ibaraki, JP)
Assignee: Yamanouchi Pharmaceutical Co., Ltd. (Tokyo, JP)
Application Number:08/860,377
Patent Claim Types:
see list of patent claims
Compound; Composition;

Drugs Protected by US Patent 6,017,927

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Astellas VESICARE solifenacin succinate TABLET;ORAL 021518-001 Nov 19, 2004 AB RX Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Astellas VESICARE solifenacin succinate TABLET;ORAL 021518-002 Nov 19, 2004 AB RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 6,017,927

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Japan6-327045Dec 28, 1994
PCT Information
PCT FiledDecember 27, 1995PCT Application Number:PCT/JP95/02713
PCT Publication Date:July 04, 1996PCT Publication Number: WO96/20194

Non-Orange Book US Patents Family Members for Patent 6,017,927

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,174,896 Quinuclidine derivatives and medicinal composition thereof ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 6,017,927

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Farmers Insurance
Healthtrust
Queensland Health
Cantor Fitzgerald
Fuji
Cerilliant
Daiichi Sankyo
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot